Company News Summary | 29 Jun 2020
Click the print icon in your browser to print this report. Currency is in AUD unless otherwise specified
Starpharma Holdings Announces DEP irinotecan Boosts Immuno-Oncology in Colon Cancer Models
09:22:00 | Associate analysts
Original annuncemenet:DEP irinotecan boosts immuno-oncology in colon cancer models
Starpharma Holdings announced its SN-38 nanoparticle, DEP irinotecan in combination with an immunooncology (IO) agent (anti PD-1 antibody) showed superior anti-tumour activity and survival benefit in two colorectal cancer (CRC) models when compared to the anti PD-1 antibody alone. These results included improvement in both survival and efficacy in the particularly aggressive CT-26 CRC mode. IO agents are important treatments in several major cancers and the market for these agents is expected to exceed US$55bn by 2025, and include Merck's Keytruda, BMS' Yervoy and AstraZeneca's Imfinzi.
|This report appeared on www.morningstar.com.au||2020 Morningstar Australasia Pty Limited|
© Copyright 2020 Morningstar Australasia Pty Ltd ABN: 95 090 665 544 ("Morningstar"), AFSL no 240892. (a subsidiary of Morningstar, Inc.). This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written content of Morningstar. Some of the material provided is published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO").